<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01513239</url>
  </required_header>
  <id_info>
    <org_study_id>3415A-002</org_study_id>
    <secondary_id>132231</secondary_id>
    <secondary_id>2011-004994-94</secondary_id>
    <nct_id>NCT01513239</nct_id>
  </id_info>
  <brief_title>A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002)</brief_title>
  <acronym>MODIFY II</acronym>
  <official_title>A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of a Single Infusion of MK-6072 (Human Monoclonal Antibody to Clostridium Difficile Toxin B), and MK-3415A (Human Monoclonal Antibodies to Clostridium Difficile Toxin A and B) in Patients Receiving Antibiotic Therapy for Clostridium Difficile Infection (MODIFY II)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      MK-3415A is the combination of monoclonal antibodies to Clostridium (C.) difficile toxin A
      (MK-3415) and toxin B (MK-6072). This study will investigate whether: 1) treatment with
      MK-6072 or MK-3415A in addition to standard of care (SOC) antibiotic therapy will decrease
      Clostridium Difficile Infection (CDI) recurrence compared with placebo; and 2) MK-6072 and
      MK-3415A will be generally well tolerated in participants receiving SOC therapy for CDI
      compared with placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An extended 9-month follow-up to assess for CDI recurrence through Month 12 will be conducted
      in a subset of participants.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With CDI Recurrence</measure>
    <time_frame>12 weeks</time_frame>
    <description>CDI recurrence is defined as the development of a new episode of diarrhea (3 or more loose stools in 24 or fewer hours) and a positive lab stool test (local or central) for toxigenic C. difficile after clinical cure of the initial CDI episode. Clinical cure is defined as no diarrhea [2 or fewer loose stools per 24 hours] for 2 consecutive days following completion of SOC therapy for the initial CDI episode in participants who received =&lt; 14 day regimen.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With One or More Adverse Events During 4 Weeks Following Infusion Treatment</measure>
    <time_frame>Up to 4 weeks</time_frame>
    <description>An adverse event (AE) is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the medicinal product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the medicinal product, is also an adverse event.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With One or More Drug-related Adverse Events During 4 Weeks Following Infusion Treatment</measure>
    <time_frame>Up to 4 weeks</time_frame>
    <description>An adverse event (AE) is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the medicinal product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the medicinal product, is also an adverse event. A drug-related adverse event is determined by the investigator to be related to the drug.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With One or More Serious Drug-related Adverse Events During 4 Weeks Following Infusion Treatment</measure>
    <time_frame>Up to 4 weeks</time_frame>
    <description>A serious adverse event (SAE) is any AE occurring at any dose or during any use of the medicinal product that results in death; or is life threatening; or results in a persistent or significant disability/incapacity; or results in or prolongs an existing inpatient hospitalization; or is a congenital anomaly/birth defect; or other important medical events. A serious drug-related adverse event is determined by the investigator to be related to the drug.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who Discontinued Study Medication Due to an Adverse Event During 4 Weeks Following Infusion Treatment</measure>
    <time_frame>Up to 4 weeks</time_frame>
    <description>An adverse event (AE) is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the medicinal product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the medicinal product, is also an adverse event.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With One or More Infusion-specific Adverse Events on the Day of Infusion or the Day After Infusion</measure>
    <time_frame>Up to 24 hours</time_frame>
    <description>An adverse event (AE) is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the medicinal product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the medicinal product, is also an adverse event.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Global Cure</measure>
    <time_frame>12 weeks</time_frame>
    <description>Global cure is defined as the clinical cure of the initial CDI episode with no CDI recurrence through Week 12. Clinical cure is defined as no diarrhea [2 or fewer loose stools per 24 hours] for 2 consecutive days following completion of SOC therapy for the initial CDI episode in participants who received =&lt; 14 day regimen.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With CDI Recurrence in Those With Clinical Cure of the Initial CDI Episode</measure>
    <time_frame>12 weeks</time_frame>
    <description>CDI recurrence is defined as the development of a new episode of diarrhea (3 or more loose stools in 24 or fewer hours) and a positive lab stool test (local or central) for toxigenic C. difficile. Clinical cure is defined as no diarrhea [2 or fewer loose stools per 24 hours] for 2 consecutive days following completion of SOC therapy for the initial CDI episode in participants who received =&lt; 14 day regimen.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With CDI Recurrence in Those With a History of CDI in the 6 Months Prior to Enrollment</measure>
    <time_frame>12 weeks</time_frame>
    <description>CDI recurrence is defined as the development of a new episode of diarrhea (3 or more loose stools in 24 or fewer hours) and a positive lab stool test (local or central) for toxigenic C. difficile. Clinical cure is defined as no diarrhea [2 or fewer loose stools per 24 hours] for 2 consecutive days following completion of SOC therapy for the initial CDI episode in participants who received =&lt; 14 day regimen.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With CDI Recurrence in Those With the 027 Ribotype</measure>
    <time_frame>12 weeks</time_frame>
    <description>CDI recurrence is defined as the development of a new episode of diarrhea (3 or more loose stools in 24 or fewer hours) and a positive lab stool test (local or central) for toxigenic C. difficile. Clinical cure is defined as no diarrhea [2 or fewer loose stools per 24 hours] for 2 consecutive days following completion of SOC therapy for the initial CDI episode in participants who received =&lt; 14 day regimen. The 027 ribotype is a more virulent, epidemic strain responsible for several outbreaks of disease associated with an increased risk of severity and mortality.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With CDI Recurrence in Those With an Epidemic Strain</measure>
    <time_frame>12 weeks</time_frame>
    <description>CDI recurrence is defined as the development of a new episode of diarrhea (3 or more loose stools in 24 or fewer hours) and a positive lab stool test (local or central) for toxigenic C. difficile. Clinical cure is defined as no diarrhea [2 or fewer loose stools per 24 hours] for 2 consecutive days following completion of SOC therapy for the initial CDI episode in participants who received =&lt; 14 day regimen. An epidemic strain includes ribotypes 027, 014, 002, 001, 106 or 020.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With CDI Recurrence in Those With Clinically Severe CDI</measure>
    <time_frame>12 weeks</time_frame>
    <description>CDI recurrence is defined as the development of a new episode of diarrhea (3 or more loose stools in 24 or fewer hours) and a positive lab stool test (local or central) for toxigenic C. difficile. Clinical cure is defined as no diarrhea [2 or fewer loose stools per 24 hours] for 2 consecutive days following completion of SOC therapy for the initial CDI episode in participants who received =&lt; 14 day regimen. Participants with clinically severe CDI have a Zar Score greater than or equal to 2 points based on the presence of 1 or more of the following: 1) age &gt;60 years old (1 point); 2) body temperature &gt;38.3°C (&gt;100°F) (1 point); 3) albumin level ˂2.5 mg/dl (1 point); 4) peripheral white blood cell count &gt;15,000 cells/mm^3 within 48 hours (1 point); 5) endoscopic evidence of pseudomembranous colitis (2 points); and 6) treatment in Intensive Care Unit (2 points).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With CDI Recurrence in Those 65 Years and Older</measure>
    <time_frame>12 weeks</time_frame>
    <description>CDI recurrence is defined as the development of a new episode of diarrhea (3 or more loose stools in 24 or fewer hours) and a positive lab stool test (local or central) for toxigenic C. difficile. Clinical cure is defined as no diarrhea [2 or fewer loose stools per 24 hours] for 2 consecutive days following completion of SOC therapy for the initial CDI episode in participants who received =&lt; 14 day regimen.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With CDI Recurrence in Those With Compromised Immunity</measure>
    <time_frame>12 weeks</time_frame>
    <description>CDI recurrence is defined as the development of a new episode of diarrhea (3 or more loose stools in 24 or fewer hours) and a positive lab stool test (local or central) for toxigenic C. difficile. Clinical cure is defined as no diarrhea [2 or fewer loose stools per 24 hours] for 2 consecutive days following completion of SOC therapy for the initial CDI episode in participants who received =&lt; 14 day regimen. Compromised immunity is an active hematological malignancy (including leukemia, lymphoma, multiple myeloma), an active malignancy requiring recent cytotoxic chemotherapy, receipt of a prior hematopoietic stem cell transplant, receipt of a prior solid organ transplant, asplenia, or neutropenia/pancytopenia due to other conditions.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1203</enrollment>
  <condition>Clostridium Difficile Infection</condition>
  <arm_group>
    <arm_group_label>MK-6072 + SOC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single intravenous (IV) infusion of 10 mg/kg MK-6072 + Standard of Care (SOC) for CDI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MK-3415A + SOC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single IV infusion of 10 mg/kg MK-3415A + SOC for CDI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + SOC</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal saline IV infusion (0.9% sodium chloride) + SOC for CDI</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MK-6072</intervention_name>
    <description>Single IV infusion of MK-6072 (10 mg/kg of monoclonal antibody to C. difficile Toxin B)</description>
    <arm_group_label>MK-6072 + SOC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MK-3415A</intervention_name>
    <description>Single IV infusion of MK-3415A (10 mg/kg of monoclonal antibody to C. difficile Toxin A and 10 mg/kg of monoclonal antibody to C. difficile Toxin B)</description>
    <arm_group_label>MK-3415A + SOC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Single IV infusion of normal saline (0.9% sodium chloride)</description>
    <arm_group_label>Placebo + SOC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SOC</intervention_name>
    <description>SOC for CDI will be prescribed for 10 to 14 days and can begin on the day of study drug infusion; but the first dose must have been administered prior to or within a few hours following study drug infusion. SOC is defined as the receipt of oral metronidazole, oral vancomycin, IV metronidazole concurrent with oral vancomycin, oral fidaxomicin, or oral fidaxomicin concurrent with IV metronidazole.</description>
    <arm_group_label>MK-6072 + SOC</arm_group_label>
    <arm_group_label>MK-3415A + SOC</arm_group_label>
    <arm_group_label>Placebo + SOC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participant has a diagnosis of CDI defined as: a) presence of diarrhea (passage of 3
             or more loose stools in 24 or fewer hours); and b) positive test for toxigenic C.
             difficile from a stool collected no more than 7 days before study infusion.

          -  Participant is receiving SOC therapy (i.e., oral metronidazole, oral vancomycin, IV
             metronidazole concurrent with oral vancomycin, oral fidaxomicin, or oral fidaxomicin
             concurrent with IV metronidazole) for CDI.

          -  Participant is highly unlikely to become pregnant or to impregnate a partner by
             meeting at least one of the following criteria: a) females not of reproductive
             potential (i.e., one who has either (1) reached natural menopause, defined as 6 months
             of spontaneous amenorrhea with serum follicle stimulating hormone [FSH] levels in the
             postmenopausal range, or 12 months of spontaneous amenorrhea not including cases with
             an underlying disease, such as anorexia nervosa, that causes amenorrhea; (2) 6 weeks
             post surgical bilateral oophorectomy with or without hysterectomy; or (3) bilateral
             tubal ligation); or b) participants of reproductive potential who agree to remain
             abstinent or use (or have their partner use) two acceptable methods of birth control
             (i.e., intrauterine device [IUD], diaphragm with spermicide; contraceptive sponge,
             condom, vasectomy and any registered and marketed hormonal contraceptives that contain
             an estrogen and/or progestational agent including oral, subcutaneous, intrauterine, or
             intramuscular agents) starting at enrollment and throughout the 12-week study.

        Exclusion Criteria:

          -  Participant with an uncontrolled chronic diarrheal illness such that their normal
             24-hour bowel movement habit is 3 or more loose stools.

          -  Participant with planned surgery for CDI within 24 hours.

          -  Female participant with a positive pregnancy test in the 48 hours before infusion and
             pre-menopausal females who are not sterilized and therefore have the potential to bear
             a child who are unwilling to undergo pregnancy testing.

          -  Female participant breast feeding or planning to breast feed before completion of the
             12-week study.

          -  Female participant planning to donate ova before completion of the 12-week study and
             male participants planning to impregnate or donate sperm before completion of the
             12-week study.

          -  Participant has previously participated in this study, has previously received MK-3415
             or MK-6072 (either alone or in combination), has received a C. difficile vaccine, or
             has received another experimental monoclonal antibody against C. difficile toxin A or
             B.

          -  Participant plans to donate blood and/or blood products within 6 months after
             infusion.

          -  Participant has received immune globulin within 6 months before infusion or is
             planning to receive immune globulin before completion of the 12-week study.

          -  Treatment with SOC therapy is planned for longer than 14 days.

          -  Participant has received more than a 24-hour regimen of cholestyramine, colestimide,
             rifaximin, or nitazoxanide within 14 days before infusion or plans to receive these
             medication before completion of the 12-week study period.

          -  Participant plans to take medications that are given to decrease gastrointestinal
             peristalsis, such as loperamide (Imodium™) or diphenoxylate hydrochloride/atropine
             sulfate (Lomotil™) any time during the 14 days after infusion. Participants receiving
             opioid medications at the onset of diarrhea may be included if they are on a stable
             dose or if there is anticipation of a dose decrease or cessation of use.

          -  Participant plans to take the probiotic Saccaromyces boulardii or plans to receive
             fecal transplantation therapy, or any other therapies that have been demonstrated to
             decrease CDI recurrence at any time after infusion (Day 1) and through completion of
             the 12-week study period.

          -  Participant has received another investigational study agent within the past 30 days
             or is currently participating in or scheduled to participate in any other clinical
             study with an investigational agent during the 12-week study.

          -  Participant is not expected to survive for 72 hours.

          -  Participant has any other condition that, in the opinion of the investigator, would
             jeopardize the safety or rights of the participant, would make it unlikely for the
             participant to complete the study, or would confound the results of the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Argentina</country>
    <country>Canada</country>
    <country>Czech Republic</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>Taiwan</country>
    <country>Turkey</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 16, 2012</study_first_submitted>
  <study_first_submitted_qc>January 19, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 20, 2012</study_first_posted>
  <results_first_submitted>October 24, 2016</results_first_submitted>
  <results_first_submitted_qc>October 24, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 15, 2016</results_first_posted>
  <last_update_submitted>January 24, 2018</last_update_submitted>
  <last_update_submitted_qc>January 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Clostridium difficile</keyword>
  <keyword>Clostridium difficile infection (CDI)</keyword>
  <keyword>recurrent Clostridium difficile</keyword>
  <keyword>vancomycin</keyword>
  <keyword>metronidazole</keyword>
  <keyword>monoclonal antibody</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Vancomycin</mesh_term>
    <mesh_term>Metronidazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
http://engagezone.msd.com/ds_documentation.php</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Male and female participants 18 years of age or older, diagnosed with Clostridium difficile infection (CDI) and receiving Standard of Care (SOC) therapy were recruited for this trial.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>MK-3415A + SOC</title>
          <description>Single intravenous (IV) infusion of 10 mg/kg MK-3415A + SOC for CDI</description>
        </group>
        <group group_id="P2">
          <title>MK-6072 + SOC</title>
          <description>Single IV infusion of 10 mg/kg MK-6072 + SOC for CDI</description>
        </group>
        <group group_id="P3">
          <title>Placebo + SOC</title>
          <description>Normal saline IV infusion (0.9% sodium chloride) + SOC for CDI</description>
        </group>
        <group group_id="P4">
          <title>MK-3415A + SOC 9-ME</title>
          <description>9 Month Extension (9-ME) for participants treated with a single IV infusion of 10 mg/kg MK-3415A + SOC</description>
        </group>
        <group group_id="P5">
          <title>MK-6072 + SOC 9-ME</title>
          <description>9-ME for participants treated with a single IV infusion of 10 mg/kg MK-6072 + SOC</description>
        </group>
        <group group_id="P6">
          <title>Placebo + SOC 9-ME</title>
          <description>9-ME for participants treated with Placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1: Main Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="397">Randomized participants</participants>
                <participants group_id="P2" count="407">Randomized participants</participants>
                <participants group_id="P3" count="399">Randomized participants</participants>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="391">Treated participants</participants>
                <participants group_id="P2" count="396">Treated participants</participants>
                <participants group_id="P3" count="381">Treated participants</participants>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>All Participants as Treated</title>
              <participants_list>
                <participants group_id="P1" count="390">One participant randomized to receive MK-3415A (MK-3415 plus MK-6072) received only MK-3415</participants>
                <participants group_id="P2" count="396">Treatment actually received</participants>
                <participants group_id="P3" count="381">Treatment actually received</participants>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="322"/>
                <participants group_id="P2" count="337"/>
                <participants group_id="P3" count="311"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="75"/>
                <participants group_id="P2" count="70"/>
                <participants group_id="P3" count="88"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="32"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Technical Problems</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="29"/>
                <participants group_id="P3" count="42"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 2: 9 Month Extension Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="112"/>
                <participants group_id="P5" count="100"/>
                <participants group_id="P6" count="83"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="102"/>
                <participants group_id="P5" count="90"/>
                <participants group_id="P6" count="78"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="10"/>
                <participants group_id="P5" count="10"/>
                <participants group_id="P6" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Technical Problems</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All Randomized Participants</population>
      <group_list>
        <group group_id="B1">
          <title>MK-3415A + SOC</title>
          <description>Single intravenous (IV) infusion of 10 mg/kg MK-3415A + SOC for CDI</description>
        </group>
        <group group_id="B2">
          <title>MK-6072 + SOC</title>
          <description>Single IV infusion of 10 mg/kg MK-6072 + SOC for CDI</description>
        </group>
        <group group_id="B3">
          <title>Placebo + SOC</title>
          <description>Normal saline IV infusion (0.9% sodium chloride) + SOC for CDI</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="397"/>
            <count group_id="B2" value="407"/>
            <count group_id="B3" value="399"/>
            <count group_id="B4" value="1203"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65.9" spread="17.3"/>
                    <measurement group_id="B2" value="62.6" spread="17.5"/>
                    <measurement group_id="B3" value="64.3" spread="16.4"/>
                    <measurement group_id="B4" value="64.2" spread="17.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="216"/>
                    <measurement group_id="B2" value="220"/>
                    <measurement group_id="B3" value="239"/>
                    <measurement group_id="B4" value="675"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="181"/>
                    <measurement group_id="B2" value="187"/>
                    <measurement group_id="B3" value="160"/>
                    <measurement group_id="B4" value="528"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With CDI Recurrence</title>
        <description>CDI recurrence is defined as the development of a new episode of diarrhea (3 or more loose stools in 24 or fewer hours) and a positive lab stool test (local or central) for toxigenic C. difficile after clinical cure of the initial CDI episode. Clinical cure is defined as no diarrhea [2 or fewer loose stools per 24 hours] for 2 consecutive days following completion of SOC therapy for the initial CDI episode in participants who received =&lt; 14 day regimen.</description>
        <time_frame>12 weeks</time_frame>
        <population>The (Full Analysis Set) FAS population consisting of all randomized participants with participants excluded for the failure to receive infusion of study medication; for lack of a positive local stool test for toxigenic C. difficile; or for failure to receive protocol defined standard of care therapy within a 1 day window of the infusion.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-3415A + SOC</title>
            <description>Single intravenous (IV) infusion of 10 mg/kg MK-3415A + SOC for CDI</description>
          </group>
          <group group_id="O2">
            <title>MK-6072 + SOC</title>
            <description>Single IV infusion of 10 mg/kg MK-6072 + SOC for CDI</description>
          </group>
          <group group_id="O3">
            <title>Placebo + SOC</title>
            <description>Normal saline IV infusion (0.9% sodium chloride) + SOC for CDI</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With CDI Recurrence</title>
          <description>CDI recurrence is defined as the development of a new episode of diarrhea (3 or more loose stools in 24 or fewer hours) and a positive lab stool test (local or central) for toxigenic C. difficile after clinical cure of the initial CDI episode. Clinical cure is defined as no diarrhea [2 or fewer loose stools per 24 hours] for 2 consecutive days following completion of SOC therapy for the initial CDI episode in participants who received =&lt; 14 day regimen.</description>
          <population>The (Full Analysis Set) FAS population consisting of all randomized participants with participants excluded for the failure to receive infusion of study medication; for lack of a positive local stool test for toxigenic C. difficile; or for failure to receive protocol defined standard of care therapy within a 1 day window of the infusion.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="390"/>
                <count group_id="O2" value="395"/>
                <count group_id="O3" value="378"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.9"/>
                    <measurement group_id="O2" value="15.7"/>
                    <measurement group_id="O3" value="25.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient)</p_value_desc>
            <method>Miettinen and Nurminen</method>
            <param_type>Adjusted Difference</param_type>
            <param_value>-10.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-16.4</ci_lower_limit>
            <ci_upper_limit>-5.1</ci_upper_limit>
            <estimate_desc>MK-3415A + SOC minus Placebo + SOC</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0003</p_value>
            <p_value_desc>One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient)</p_value_desc>
            <method>Miettinen and Nurminen</method>
            <param_type>Adjusted Difference</param_type>
            <param_value>-9.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-15.5</ci_lower_limit>
            <ci_upper_limit>-4.3</ci_upper_limit>
            <estimate_desc>MK-6072 + SOC minus Placebo + SOC</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3718</p_value>
            <p_value_desc>One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient)</p_value_desc>
            <method>Miettinen and Nurminen</method>
            <param_type>Adjusted Difference</param_type>
            <param_value>-0.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.9</ci_lower_limit>
            <ci_upper_limit>4.2</ci_upper_limit>
            <estimate_desc>MK-3415A + SOC minus MK-6072 + SOC</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Global Cure</title>
        <description>Global cure is defined as the clinical cure of the initial CDI episode with no CDI recurrence through Week 12. Clinical cure is defined as no diarrhea [2 or fewer loose stools per 24 hours] for 2 consecutive days following completion of SOC therapy for the initial CDI episode in participants who received =&lt; 14 day regimen.</description>
        <time_frame>12 weeks</time_frame>
        <population>The FAS population consisting of all randomized participants with participants excluded for the failure to receive infusion of study medication; for lack of a positive local stool test for toxigenic C. difficile; or for failure to receive protocol defined standard of care therapy within a 1 day window of the infusion.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-3415A + SOC</title>
            <description>Single intravenous (IV) infusion of 10 mg/kg MK-3415A + SOC for CDI</description>
          </group>
          <group group_id="O2">
            <title>MK-6072 + SOC</title>
            <description>Single IV infusion of 10 mg/kg MK-6072 + SOC for CDI</description>
          </group>
          <group group_id="O3">
            <title>Placebo + SOC</title>
            <description>Normal saline IV infusion (0.9% sodium chloride) + SOC for CDI</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Global Cure</title>
          <description>Global cure is defined as the clinical cure of the initial CDI episode with no CDI recurrence through Week 12. Clinical cure is defined as no diarrhea [2 or fewer loose stools per 24 hours] for 2 consecutive days following completion of SOC therapy for the initial CDI episode in participants who received =&lt; 14 day regimen.</description>
          <population>The FAS population consisting of all randomized participants with participants excluded for the failure to receive infusion of study medication; for lack of a positive local stool test for toxigenic C. difficile; or for failure to receive protocol defined standard of care therapy within a 1 day window of the infusion.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="390"/>
                <count group_id="O2" value="395"/>
                <count group_id="O3" value="378"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.4"/>
                    <measurement group_id="O2" value="66.8"/>
                    <measurement group_id="O3" value="52.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0722</p_value>
            <p_value_desc>One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient)</p_value_desc>
            <method>Miettinen and Nurminen</method>
            <param_type>Adjusted Difference</param_type>
            <param_value>5.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.8</ci_lower_limit>
            <ci_upper_limit>12.2</ci_upper_limit>
            <estimate_desc>MK-3415A + SOC minus Placebo + SOC</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient)</p_value_desc>
            <method>Miettinen and Nurminen</method>
            <param_type>Adjusted Difference</param_type>
            <param_value>14.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>7.7</ci_lower_limit>
            <ci_upper_limit>21.4</ci_upper_limit>
            <estimate_desc>MK-6072 + SOC minus Placebo + SOC</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9969</p_value>
            <p_value_desc>One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient)</p_value_desc>
            <method>Miettinen and Nurminen</method>
            <param_type>Adjusted Difference</param_type>
            <param_value>-9.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-16.1</ci_lower_limit>
            <ci_upper_limit>-2.7</ci_upper_limit>
            <estimate_desc>MK-3415A + SOC minus MK-6072 + SOC</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With CDI Recurrence in Those With Clinical Cure of the Initial CDI Episode</title>
        <description>CDI recurrence is defined as the development of a new episode of diarrhea (3 or more loose stools in 24 or fewer hours) and a positive lab stool test (local or central) for toxigenic C. difficile. Clinical cure is defined as no diarrhea [2 or fewer loose stools per 24 hours] for 2 consecutive days following completion of SOC therapy for the initial CDI episode in participants who received =&lt; 14 day regimen.</description>
        <time_frame>12 weeks</time_frame>
        <population>Treated participants who achieved a clinical cure of the initial CDI episode.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-3415A + SOC</title>
            <description>Single intravenous (IV) infusion of 10 mg/kg MK-3415A + SOC for CDI</description>
          </group>
          <group group_id="O2">
            <title>MK-6072 + SOC</title>
            <description>Single IV infusion of 10 mg/kg MK-6072 + SOC for CDI</description>
          </group>
          <group group_id="O3">
            <title>Placebo + SOC</title>
            <description>Normal saline IV infusion (0.9% sodium chloride) + SOC for CDI</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With CDI Recurrence in Those With Clinical Cure of the Initial CDI Episode</title>
          <description>CDI recurrence is defined as the development of a new episode of diarrhea (3 or more loose stools in 24 or fewer hours) and a positive lab stool test (local or central) for toxigenic C. difficile. Clinical cure is defined as no diarrhea [2 or fewer loose stools per 24 hours] for 2 consecutive days following completion of SOC therapy for the initial CDI episode in participants who received =&lt; 14 day regimen.</description>
          <population>Treated participants who achieved a clinical cure of the initial CDI episode.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="282"/>
                <count group_id="O2" value="326"/>
                <count group_id="O3" value="294"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.6"/>
                    <measurement group_id="O2" value="19.0"/>
                    <measurement group_id="O3" value="33.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0006</p_value>
            <p_value_desc>One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient)</p_value_desc>
            <method>Miettinen and Nurminen</method>
            <param_type>Adjusted Difference</param_type>
            <param_value>-11.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-19.0</ci_lower_limit>
            <ci_upper_limit>-4.7</ci_upper_limit>
            <estimate_desc>MK-3415A + SOC minus Placebo + SOC</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient)</p_value_desc>
            <method>Miettinen and Nurminen</method>
            <param_type>Adjusted Difference</param_type>
            <param_value>-13.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-20.4</ci_lower_limit>
            <ci_upper_limit>-6.9</ci_upper_limit>
            <estimate_desc>MK-6072 + SOC minus Placebo + SOC</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6962</p_value>
            <p_value_desc>One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient)</p_value_desc>
            <method>Miettinen and Nurminen</method>
            <param_type>Adjusted Difference</param_type>
            <param_value>1.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.6</ci_lower_limit>
            <ci_upper_limit>8.0</ci_upper_limit>
            <estimate_desc>MK-3415A + SOC minus MK-6072 + SOC</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With One or More Adverse Events During 4 Weeks Following Infusion Treatment</title>
        <description>An adverse event (AE) is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the medicinal product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the medicinal product, is also an adverse event.</description>
        <time_frame>Up to 4 weeks</time_frame>
        <population>All Participants as Treated (APaT), based on the treatment actually received. One participant randomized to the MK- 3415A + SOC arm who was treated with MK-3415, but was not treated with MK-6072, was not analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-3415A + SOC</title>
            <description>Single intravenous (IV) infusion of 10 mg/kg MK-3415A + SOC for CDI</description>
          </group>
          <group group_id="O2">
            <title>MK-6072 + SOC</title>
            <description>Single IV infusion of 10 mg/kg MK-6072 + SOC for CDI</description>
          </group>
          <group group_id="O3">
            <title>Placebo + SOC</title>
            <description>Normal saline IV infusion (0.9% sodium chloride) + SOC for CDI</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With One or More Adverse Events During 4 Weeks Following Infusion Treatment</title>
          <description>An adverse event (AE) is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the medicinal product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the medicinal product, is also an adverse event.</description>
          <population>All Participants as Treated (APaT), based on the treatment actually received. One participant randomized to the MK- 3415A + SOC arm who was treated with MK-3415, but was not treated with MK-6072, was not analyzed.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="390"/>
                <count group_id="O2" value="396"/>
                <count group_id="O3" value="381"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.4"/>
                    <measurement group_id="O2" value="58.1"/>
                    <measurement group_id="O3" value="60.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.408</p_value>
            <method>Miettinen and Nurminen</method>
            <param_type>Difference in Percentages</param_type>
            <param_value>-2.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.8</ci_lower_limit>
            <ci_upper_limit>4.0</ci_upper_limit>
            <estimate_desc>MK-3415A + SOC minus Placebo +SOC</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.517</p_value>
            <method>Miettinen and Nurminen</method>
            <param_type>Difference in Percentages</param_type>
            <param_value>-2.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.2</ci_lower_limit>
            <ci_upper_limit>4.6</ci_upper_limit>
            <estimate_desc>MK-6072 + SOC minus Placebo + SOC</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With One or More Drug-related Adverse Events During 4 Weeks Following Infusion Treatment</title>
        <description>An adverse event (AE) is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the medicinal product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the medicinal product, is also an adverse event. A drug-related adverse event is determined by the investigator to be related to the drug.</description>
        <time_frame>Up to 4 weeks</time_frame>
        <population>APaT based on the treatment actually received. One participant randomized to the MK-3415A + SOC arm who was treated with MK-3415, but was not treated with MK-6072, was not analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-3415A + SOC</title>
            <description>Single intravenous (IV) infusion of 10 mg/kg MK-3415A + SOC for CDI</description>
          </group>
          <group group_id="O2">
            <title>MK-6072 + SOC</title>
            <description>Single IV infusion of 10 mg/kg MK-6072 + SOC for CDI</description>
          </group>
          <group group_id="O3">
            <title>Placebo + SOC</title>
            <description>Normal saline IV infusion (0.9% sodium chloride) + SOC for CDI</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With One or More Drug-related Adverse Events During 4 Weeks Following Infusion Treatment</title>
          <description>An adverse event (AE) is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the medicinal product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the medicinal product, is also an adverse event. A drug-related adverse event is determined by the investigator to be related to the drug.</description>
          <population>APaT based on the treatment actually received. One participant randomized to the MK-3415A + SOC arm who was treated with MK-3415, but was not treated with MK-6072, was not analyzed.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="390"/>
                <count group_id="O2" value="396"/>
                <count group_id="O3" value="381"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7"/>
                    <measurement group_id="O2" value="6.8"/>
                    <measurement group_id="O3" value="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.931</p_value>
            <method>Miettinen and Nurminen</method>
            <param_type>Difference in Percentages</param_type>
            <param_value>-0.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.8</ci_lower_limit>
            <ci_upper_limit>3.5</ci_upper_limit>
            <estimate_desc>MK-3415A + SOC minus Placebo + SOC</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.997</p_value>
            <method>Miettinen and Nurminen</method>
            <param_type>Difference in Percentages</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.7</ci_lower_limit>
            <ci_upper_limit>3.6</ci_upper_limit>
            <estimate_desc>MK-6072 + SOC minus Placebo + SOC</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With One or More Serious Drug-related Adverse Events During 4 Weeks Following Infusion Treatment</title>
        <description>A serious adverse event (SAE) is any AE occurring at any dose or during any use of the medicinal product that results in death; or is life threatening; or results in a persistent or significant disability/incapacity; or results in or prolongs an existing inpatient hospitalization; or is a congenital anomaly/birth defect; or other important medical events. A serious drug-related adverse event is determined by the investigator to be related to the drug.</description>
        <time_frame>Up to 4 weeks</time_frame>
        <population>APaT based on the treatment actually received. One participant randomized to the MK-3415A + SOC arm who was treated with MK-3415, but was not treated with MK-6072, was not analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-3415A + SOC</title>
            <description>Single intravenous (IV) infusion of 10 mg/kg MK-3415A + SOC for CDI</description>
          </group>
          <group group_id="O2">
            <title>MK-6072 + SOC</title>
            <description>Single IV infusion of 10 mg/kg MK-6072 + SOC for CDI</description>
          </group>
          <group group_id="O3">
            <title>Placebo + SOC</title>
            <description>Normal saline IV infusion (0.9% sodium chloride) + SOC for CDI</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With One or More Serious Drug-related Adverse Events During 4 Weeks Following Infusion Treatment</title>
          <description>A serious adverse event (SAE) is any AE occurring at any dose or during any use of the medicinal product that results in death; or is life threatening; or results in a persistent or significant disability/incapacity; or results in or prolongs an existing inpatient hospitalization; or is a congenital anomaly/birth defect; or other important medical events. A serious drug-related adverse event is determined by the investigator to be related to the drug.</description>
          <population>APaT based on the treatment actually received. One participant randomized to the MK-3415A + SOC arm who was treated with MK-3415, but was not treated with MK-6072, was not analyzed.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="390"/>
                <count group_id="O2" value="396"/>
                <count group_id="O3" value="381"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.328</p_value>
            <method>Miettinen and Nurminen</method>
            <param_type>Difference in Percentages</param_type>
            <param_value>0.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.8</ci_lower_limit>
            <ci_upper_limit>2.0</ci_upper_limit>
            <estimate_desc>MK-3415A + SOC minus Placebo + SOC</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.308</p_value>
            <method>Miettinen and Nurminen</method>
            <param_type>Difference in Percentages</param_type>
            <param_value>-0.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.5</ci_lower_limit>
            <ci_upper_limit>0.7</ci_upper_limit>
            <estimate_desc>MK-6072 + SOC minus Placebo + SOC</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Who Discontinued Study Medication Due to an Adverse Event During 4 Weeks Following Infusion Treatment</title>
        <description>An adverse event (AE) is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the medicinal product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the medicinal product, is also an adverse event.</description>
        <time_frame>Up to 4 weeks</time_frame>
        <population>APaT based on the treatment actually received. One participant randomized to the MK-3415A + SOC arm who was treated with MK-3415, but was not treated with MK-6072, was not analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-3415A + SOC</title>
            <description>Single intravenous (IV) infusion of 10 mg/kg MK-3415A + SOC for CDI</description>
          </group>
          <group group_id="O2">
            <title>MK-6072 + SOC</title>
            <description>Single IV infusion of 10 mg/kg MK-6072 + SOC for CDI</description>
          </group>
          <group group_id="O3">
            <title>Placebo + SOC</title>
            <description>Normal saline IV infusion (0.9% sodium chloride) + SOC for CDI</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Discontinued Study Medication Due to an Adverse Event During 4 Weeks Following Infusion Treatment</title>
          <description>An adverse event (AE) is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the medicinal product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the medicinal product, is also an adverse event.</description>
          <population>APaT based on the treatment actually received. One participant randomized to the MK-3415A + SOC arm who was treated with MK-3415, but was not treated with MK-6072, was not analyzed.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="390"/>
                <count group_id="O2" value="396"/>
                <count group_id="O3" value="381"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.999</p_value>
            <method>Miettinen and Nurminen</method>
            <param_type>Difference in Percentages</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.0</ci_lower_limit>
            <ci_upper_limit>1.0</ci_upper_limit>
            <estimate_desc>MK-3415A + SOC minus Placebo + SOC</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.999</p_value>
            <method>Miettinen and Nurminen</method>
            <param_type>Difference in Percentages</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.0</ci_lower_limit>
            <ci_upper_limit>1.0</ci_upper_limit>
            <estimate_desc>MK-6072 + SOC minus Placebo + SOC</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With One or More Infusion-specific Adverse Events on the Day of Infusion or the Day After Infusion</title>
        <description>An adverse event (AE) is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the medicinal product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the medicinal product, is also an adverse event.</description>
        <time_frame>Up to 24 hours</time_frame>
        <population>APaT based on the treatment actually received. One participant randomized to the MK-3415A + SOC arm who was treated with MK-3415, but was not treated with MK-6072, was not analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-3415A + SOC</title>
            <description>Single intravenous (IV) infusion of 10 mg/kg MK-3415A + SOC for CDI</description>
          </group>
          <group group_id="O2">
            <title>MK-6072 + SOC</title>
            <description>Single IV infusion of 10 mg/kg MK-6072 + SOC for CDI</description>
          </group>
          <group group_id="O3">
            <title>Placebo + SOC</title>
            <description>Normal saline IV infusion (0.9% sodium chloride) + SOC for CDI</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With One or More Infusion-specific Adverse Events on the Day of Infusion or the Day After Infusion</title>
          <description>An adverse event (AE) is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the medicinal product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the medicinal product, is also an adverse event.</description>
          <population>APaT based on the treatment actually received. One participant randomized to the MK-3415A + SOC arm who was treated with MK-3415, but was not treated with MK-6072, was not analyzed.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="390"/>
                <count group_id="O2" value="396"/>
                <count group_id="O3" value="381"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.2"/>
                    <measurement group_id="O2" value="8.8"/>
                    <measurement group_id="O3" value="7.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in Percentages</param_type>
            <param_value>-0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.2</ci_lower_limit>
            <ci_upper_limit>3.3</ci_upper_limit>
            <estimate_desc>MK-3415A + SOC minus Placebo + SOC</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in Percentages</param_type>
            <param_value>1.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.7</ci_lower_limit>
            <ci_upper_limit>5.2</ci_upper_limit>
            <estimate_desc>MK-6072 + SOC minus Placebo + SOC</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With CDI Recurrence in Those With a History of CDI in the 6 Months Prior to Enrollment</title>
        <description>CDI recurrence is defined as the development of a new episode of diarrhea (3 or more loose stools in 24 or fewer hours) and a positive lab stool test (local or central) for toxigenic C. difficile. Clinical cure is defined as no diarrhea [2 or fewer loose stools per 24 hours] for 2 consecutive days following completion of SOC therapy for the initial CDI episode in participants who received =&lt; 14 day regimen.</description>
        <time_frame>12 weeks</time_frame>
        <population>Treated participants with a history of CDI in the past 6 months.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-3415A + SOC</title>
            <description>Single intravenous (IV) infusion of 10 mg/kg MK-3415A + SOC for CDI</description>
          </group>
          <group group_id="O2">
            <title>MK-6072 + SOC</title>
            <description>Single IV infusion of 10 mg/kg MK-6072 + SOC for CDI</description>
          </group>
          <group group_id="O3">
            <title>Placebo + SOC</title>
            <description>Normal saline IV infusion (0.9% sodium chloride) + SOC for CDI</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With CDI Recurrence in Those With a History of CDI in the 6 Months Prior to Enrollment</title>
          <description>CDI recurrence is defined as the development of a new episode of diarrhea (3 or more loose stools in 24 or fewer hours) and a positive lab stool test (local or central) for toxigenic C. difficile. Clinical cure is defined as no diarrhea [2 or fewer loose stools per 24 hours] for 2 consecutive days following completion of SOC therapy for the initial CDI episode in participants who received =&lt; 14 day regimen.</description>
          <population>Treated participants with a history of CDI in the past 6 months.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
                <count group_id="O2" value="113"/>
                <count group_id="O3" value="110"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.2"/>
                    <measurement group_id="O2" value="23.9"/>
                    <measurement group_id="O3" value="42.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With CDI Recurrence in Those With the 027 Ribotype</title>
        <description>CDI recurrence is defined as the development of a new episode of diarrhea (3 or more loose stools in 24 or fewer hours) and a positive lab stool test (local or central) for toxigenic C. difficile. Clinical cure is defined as no diarrhea [2 or fewer loose stools per 24 hours] for 2 consecutive days following completion of SOC therapy for the initial CDI episode in participants who received =&lt; 14 day regimen. The 027 ribotype is a more virulent, epidemic strain responsible for several outbreaks of disease associated with an increased risk of severity and mortality.</description>
        <time_frame>12 weeks</time_frame>
        <population>Treated participants with the 027 ribotype</population>
        <group_list>
          <group group_id="O1">
            <title>MK-3415A + SOC</title>
            <description>Single intravenous (IV) infusion of 10 mg/kg MK-3415A + SOC for CDI</description>
          </group>
          <group group_id="O2">
            <title>MK-6072 + SOC</title>
            <description>Single IV infusion of 10 mg/kg MK-6072 + SOC for CDI</description>
          </group>
          <group group_id="O3">
            <title>Placebo + SOC</title>
            <description>Normal saline IV infusion (0.9% sodium chloride) + SOC for CDI</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With CDI Recurrence in Those With the 027 Ribotype</title>
          <description>CDI recurrence is defined as the development of a new episode of diarrhea (3 or more loose stools in 24 or fewer hours) and a positive lab stool test (local or central) for toxigenic C. difficile. Clinical cure is defined as no diarrhea [2 or fewer loose stools per 24 hours] for 2 consecutive days following completion of SOC therapy for the initial CDI episode in participants who received =&lt; 14 day regimen. The 027 ribotype is a more virulent, epidemic strain responsible for several outbreaks of disease associated with an increased risk of severity and mortality.</description>
          <population>Treated participants with the 027 ribotype</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="43"/>
                <count group_id="O3" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.8"/>
                    <measurement group_id="O2" value="20.9"/>
                    <measurement group_id="O3" value="32.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With CDI Recurrence in Those With an Epidemic Strain</title>
        <description>CDI recurrence is defined as the development of a new episode of diarrhea (3 or more loose stools in 24 or fewer hours) and a positive lab stool test (local or central) for toxigenic C. difficile. Clinical cure is defined as no diarrhea [2 or fewer loose stools per 24 hours] for 2 consecutive days following completion of SOC therapy for the initial CDI episode in participants who received =&lt; 14 day regimen. An epidemic strain includes ribotypes 027, 014, 002, 001, 106 or 020.</description>
        <time_frame>12 weeks</time_frame>
        <population>Treated participants with an epidemic strain</population>
        <group_list>
          <group group_id="O1">
            <title>MK-3415A + SOC</title>
            <description>Single intravenous (IV) infusion of 10 mg/kg MK-3415A + SOC for CDI</description>
          </group>
          <group group_id="O2">
            <title>MK-6072 + SOC</title>
            <description>Single IV infusion of 10 mg/kg MK-6072 + SOC for CDI</description>
          </group>
          <group group_id="O3">
            <title>Placebo + SOC</title>
            <description>Normal saline IV infusion (0.9% sodium chloride) + SOC for CDI</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With CDI Recurrence in Those With an Epidemic Strain</title>
          <description>CDI recurrence is defined as the development of a new episode of diarrhea (3 or more loose stools in 24 or fewer hours) and a positive lab stool test (local or central) for toxigenic C. difficile. Clinical cure is defined as no diarrhea [2 or fewer loose stools per 24 hours] for 2 consecutive days following completion of SOC therapy for the initial CDI episode in participants who received =&lt; 14 day regimen. An epidemic strain includes ribotypes 027, 014, 002, 001, 106 or 020.</description>
          <population>Treated participants with an epidemic strain</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="116"/>
                <count group_id="O2" value="102"/>
                <count group_id="O3" value="127"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.7"/>
                    <measurement group_id="O2" value="18.6"/>
                    <measurement group_id="O3" value="29.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With CDI Recurrence in Those With Clinically Severe CDI</title>
        <description>CDI recurrence is defined as the development of a new episode of diarrhea (3 or more loose stools in 24 or fewer hours) and a positive lab stool test (local or central) for toxigenic C. difficile. Clinical cure is defined as no diarrhea [2 or fewer loose stools per 24 hours] for 2 consecutive days following completion of SOC therapy for the initial CDI episode in participants who received =&lt; 14 day regimen. Participants with clinically severe CDI have a Zar Score greater than or equal to 2 points based on the presence of 1 or more of the following: 1) age &gt;60 years old (1 point); 2) body temperature &gt;38.3°C (&gt;100°F) (1 point); 3) albumin level ˂2.5 mg/dl (1 point); 4) peripheral white blood cell count &gt;15,000 cells/mm^3 within 48 hours (1 point); 5) endoscopic evidence of pseudomembranous colitis (2 points); and 6) treatment in Intensive Care Unit (2 points).</description>
        <time_frame>12 weeks</time_frame>
        <population>Treated participants with clinically severe CDI</population>
        <group_list>
          <group group_id="O1">
            <title>MK-3415A + SOC</title>
            <description>Single intravenous (IV) infusion of 10 mg/kg MK-3415A + SOC for CDI</description>
          </group>
          <group group_id="O2">
            <title>MK-6072 + SOC</title>
            <description>Single IV infusion of 10 mg/kg MK-6072 + SOC for CDI</description>
          </group>
          <group group_id="O3">
            <title>Placebo + SOC</title>
            <description>Normal saline IV infusion (0.9% sodium chloride) + SOC for CDI</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With CDI Recurrence in Those With Clinically Severe CDI</title>
          <description>CDI recurrence is defined as the development of a new episode of diarrhea (3 or more loose stools in 24 or fewer hours) and a positive lab stool test (local or central) for toxigenic C. difficile. Clinical cure is defined as no diarrhea [2 or fewer loose stools per 24 hours] for 2 consecutive days following completion of SOC therapy for the initial CDI episode in participants who received =&lt; 14 day regimen. Participants with clinically severe CDI have a Zar Score greater than or equal to 2 points based on the presence of 1 or more of the following: 1) age &gt;60 years old (1 point); 2) body temperature &gt;38.3°C (&gt;100°F) (1 point); 3) albumin level ˂2.5 mg/dl (1 point); 4) peripheral white blood cell count &gt;15,000 cells/mm^3 within 48 hours (1 point); 5) endoscopic evidence of pseudomembranous colitis (2 points); and 6) treatment in Intensive Care Unit (2 points).</description>
          <population>Treated participants with clinically severe CDI</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.3"/>
                    <measurement group_id="O2" value="10.9"/>
                    <measurement group_id="O3" value="20.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With CDI Recurrence in Those 65 Years and Older</title>
        <description>CDI recurrence is defined as the development of a new episode of diarrhea (3 or more loose stools in 24 or fewer hours) and a positive lab stool test (local or central) for toxigenic C. difficile. Clinical cure is defined as no diarrhea [2 or fewer loose stools per 24 hours] for 2 consecutive days following completion of SOC therapy for the initial CDI episode in participants who received =&lt; 14 day regimen.</description>
        <time_frame>12 weeks</time_frame>
        <population>Treated participants 65 years and older.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-3415A + SOC</title>
            <description>Single intravenous (IV) infusion of 10 mg/kg MK-3415A + SOC for CDI</description>
          </group>
          <group group_id="O2">
            <title>MK-6072 + SOC</title>
            <description>Single IV infusion of 10 mg/kg MK-6072 + SOC for CDI</description>
          </group>
          <group group_id="O3">
            <title>Placebo + SOC</title>
            <description>Normal saline IV infusion (0.9% sodium chloride) + SOC for CDI</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With CDI Recurrence in Those 65 Years and Older</title>
          <description>CDI recurrence is defined as the development of a new episode of diarrhea (3 or more loose stools in 24 or fewer hours) and a positive lab stool test (local or central) for toxigenic C. difficile. Clinical cure is defined as no diarrhea [2 or fewer loose stools per 24 hours] for 2 consecutive days following completion of SOC therapy for the initial CDI episode in participants who received =&lt; 14 day regimen.</description>
          <population>Treated participants 65 years and older.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="241"/>
                <count group_id="O2" value="205"/>
                <count group_id="O3" value="206"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.4"/>
                    <measurement group_id="O2" value="15.6"/>
                    <measurement group_id="O3" value="29.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With CDI Recurrence in Those With Compromised Immunity</title>
        <description>CDI recurrence is defined as the development of a new episode of diarrhea (3 or more loose stools in 24 or fewer hours) and a positive lab stool test (local or central) for toxigenic C. difficile. Clinical cure is defined as no diarrhea [2 or fewer loose stools per 24 hours] for 2 consecutive days following completion of SOC therapy for the initial CDI episode in participants who received =&lt; 14 day regimen. Compromised immunity is an active hematological malignancy (including leukemia, lymphoma, multiple myeloma), an active malignancy requiring recent cytotoxic chemotherapy, receipt of a prior hematopoietic stem cell transplant, receipt of a prior solid organ transplant, asplenia, or neutropenia/pancytopenia due to other conditions.</description>
        <time_frame>12 weeks</time_frame>
        <population>Treated participants with compromised immunity</population>
        <group_list>
          <group group_id="O1">
            <title>MK-3415A + SOC</title>
            <description>Single intravenous (IV) infusion of 10 mg/kg MK-3415A + SOC for CDI</description>
          </group>
          <group group_id="O2">
            <title>MK-6072 + SOC</title>
            <description>Single IV infusion of 10 mg/kg MK-6072 + SOC for CDI</description>
          </group>
          <group group_id="O3">
            <title>Placebo + SOC</title>
            <description>Normal saline IV infusion (0.9% sodium chloride) + SOC for CDI</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With CDI Recurrence in Those With Compromised Immunity</title>
          <description>CDI recurrence is defined as the development of a new episode of diarrhea (3 or more loose stools in 24 or fewer hours) and a positive lab stool test (local or central) for toxigenic C. difficile. Clinical cure is defined as no diarrhea [2 or fewer loose stools per 24 hours] for 2 consecutive days following completion of SOC therapy for the initial CDI episode in participants who received =&lt; 14 day regimen. Compromised immunity is an active hematological malignancy (including leukemia, lymphoma, multiple myeloma), an active malignancy requiring recent cytotoxic chemotherapy, receipt of a prior hematopoietic stem cell transplant, receipt of a prior solid organ transplant, asplenia, or neutropenia/pancytopenia due to other conditions.</description>
          <population>Treated participants with compromised immunity</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
                <count group_id="O2" value="91"/>
                <count group_id="O3" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.5"/>
                    <measurement group_id="O2" value="12.1"/>
                    <measurement group_id="O3" value="26.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Non-serious adverse events up to Day 28; serious adverse events up to Day 90</time_frame>
      <desc>Main Phase AEs were assessed Systematically: All Participants as Treated (APaT), based on the treatment actually received. One participant randomized to the MK-3415A + SOC arm was treated with MK-3415, but was not treated with MK-6072, is placed in his own arm for MK-3415 (not a randomized arm for this study).
9-Month Extension AEs were not planned for collection; and were therefore assessed Non-systematically.</desc>
      <group_list>
        <group group_id="E1">
          <title>MK-3415A + SOC</title>
          <description>Single IV infusion of 10 mg/kg MK 3415A + SOC for CDI</description>
        </group>
        <group group_id="E2">
          <title>MK-6072 + SOC</title>
          <description>Single IV infusion of 10 mg/kg MK-6072 + SOC for CDI</description>
        </group>
        <group group_id="E3">
          <title>Placebo + SOC</title>
          <description>Normal saline IV infusion (0.9% sodium chloride) + SOC for CDI</description>
        </group>
        <group group_id="E4">
          <title>MK-3415 + SOC</title>
          <description>Single IV infusion of 10 mg/kg MK-3415 + SOC for CDI</description>
        </group>
        <group group_id="E5">
          <title>MK-3415A + SOC 9-ME</title>
          <description>9 Month Extension (9-ME) for participants treated with a single IV infusion of 10 mg/kg MK-3415A + SOC</description>
        </group>
        <group group_id="E6">
          <title>MK-6072 + SOC 9-ME</title>
          <description>9-ME for participants treated with a single IV infusion of 10 mg/kg MK-6072 + SOC</description>
        </group>
        <group group_id="E7">
          <title>Placebo + SOC 9-ME</title>
          <description>9-ME for participants treated with Placebo</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 16.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="390"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="381"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="112"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="100"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="118" subjects_at_risk="390"/>
                <counts group_id="E2" subjects_affected="111" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="129" subjects_at_risk="381"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="112"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="100"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="390"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="396"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Anaemia of malignant disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Coagulopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Disseminated intravascular coagulation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Haemolytic anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Haemorrhagic anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Sickle cell anaemia with crisis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis coronary artery</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="396"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="396"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Cardiac disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="390"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="396"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Cardiac failure chronic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="390"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Prinzmetal angina</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperparathyroidism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blindness unilateral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="2" subjects_at_risk="390"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="396"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Anal fissure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Anal fistula</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="390"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="396"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Diverticulum intestinal haemorrhagic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Gastric haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="396"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Gastrointestinal inflammation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Haemorrhagic erosive gastritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Impaired gastric emptying</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Intestinal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Intestinal perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Large intestinal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Mesenteric artery thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Oesophageal ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Subileus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="396"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Device breakage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Device malfunction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Disuse syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Drug withdrawal syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Generalised oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Impaired healing</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Pelvic mass</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Suprapubic pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Cholangitis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Hepatic cirrhosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Hepatic failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Arthritis infective</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Bursitis infective staphylococcal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Clostridium difficile infection</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="390"/>
                <counts group_id="E2" events="15" subjects_affected="14" subjects_at_risk="396"/>
                <counts group_id="E3" events="34" subjects_affected="28" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus viraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Diabetic foot infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Fungaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Gangrene</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="396"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>HIV infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Infective spondylitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Kidney infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Lung abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Meningitis tuberculous</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Necrotising fasciitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Pelvic abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Periodontitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Peritonitis bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="390"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="396"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Pseudomembranous colitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="396"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="390"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="396"/>
                <counts group_id="E3" events="14" subjects_affected="13" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="390"/>
                <counts group_id="E2" events="11" subjects_affected="9" subjects_at_risk="396"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Viraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title vocab="MedDRA version 16.1">Emphysematous cholecystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arteriovenous fistula site haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Frostbite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Intentional overdose</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Post procedural inflammation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Toxicity to various agents</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Blood lactic acid increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Blood pressure decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Escherichia test positive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>International normalised ratio increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Fluid overload</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Hypercreatininaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Shock hypoglycaemic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthritis reactive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Soft tissue necrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title vocab="MedDRA version 16.1">Osteoporotic fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Acute myeloid leukaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Acute myeloid leukaemia recurrent</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma gastric</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Bile duct cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Bone cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Bone cancer metastatic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Breast cancer metastatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Gastrointestinal cancer metastatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Glioblastoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Hepatocellular carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Hodgkin's disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Leiomyosarcoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Lung neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Lymphocytic leukaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Medulloblastoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Metastatic renal cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Metastatic squamous cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Myeloid leukaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Oesophageal carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Peripheral T-cell lymphoma unspecified</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Plasma cell myeloma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Renal cancer metastatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title vocab="MedDRA version 16.1">Bladder cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title vocab="MedDRA version 16.1">Chronic lymphocytic leukaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title vocab="MedDRA version 16.1">Lymphoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title vocab="MedDRA version 16.1">Pancreatic carcinoma metastatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Altered state of consciousness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Aphasia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Cerebellar haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="390"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Dementia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Hypoxic-ischaemic encephalopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Metabolic encephalopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Neuralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Senile dementia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Spinal cord compression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Status epilepticus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Wernicke's encephalopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title vocab="MedDRA version 16.1">Haemorrhage intracranial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Anxiety disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="381"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Calculus ureteric</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Chronic kidney disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="396"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Nephritic syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Prostatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute pulmonary oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="390"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="396"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Laryngeal stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Lung disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="390"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Pulmonary haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Respiratory arrest</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Respiratory depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="390"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="396"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract inflammation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Decubitus ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Circulatory collapse</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Dry gangrene</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Phlebitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Shock</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 16.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="390"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="37" subjects_at_risk="381"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="19" subjects_affected="17" subjects_at_risk="390"/>
                <counts group_id="E2" events="18" subjects_affected="17" subjects_at_risk="396"/>
                <counts group_id="E3" events="23" subjects_affected="21" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="390"/>
                <counts group_id="E2" events="23" subjects_affected="23" subjects_at_risk="396"/>
                <counts group_id="E3" events="12" subjects_affected="12" subjects_at_risk="381"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Clostridium difficile infection</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="390"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="396"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="381"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Neutrophil count increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="396"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="381"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>White blood cell count increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The SPONSOR must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the SPONSOR as confidential must be deleted prior to submission.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

